Heron Therapeutics Inc. (HRTX) to Post Q1 2017 Earnings of ($0.77) Per Share, Leerink Swann Forecasts
Heron Therapeutics Inc. (NASDAQ:HRTX) – Equities research analysts at Leerink Swann issued their Q1 2017 EPS estimates for shares of Heron Therapeutics in a research note issued to investors on Thursday. Leerink Swann analyst J. Gerberry forecasts that the brokerage will earn ($0.77) per share for the quarter. Leerink Swann currently has a “Buy” rating and a $33.00 target price on the stock. Leerink Swann also issued estimates for Heron Therapeutics’ Q2 2017 earnings at ($0.79) EPS, Q3 2017 earnings at ($0.60) EPS and Q4 2017 earnings at ($0.15) EPS.
HRTX has been the subject of several other research reports. Brean Capital initiated coverage on Heron Therapeutics in a research note on Tuesday. They issued a “buy” rating and a $41.00 target price for the company. Lake Street Capital reiterated a “buy” rating and issued a $45.00 price objective on shares of Heron Therapeutics in a research report on Tuesday, September 6th. JMP Securities reiterated a “buy” rating on shares of Heron Therapeutics in a research report on Friday, September 9th. Jefferies Group lowered their price objective on Heron Therapeutics from $46.00 to $40.00 and set a “buy” rating for the company in a research report on Monday. Finally, Zacks Investment Research downgraded Heron Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday. One equities research analyst has rated the stock with a sell rating and eight have given a buy rating to the company’s stock. Heron Therapeutics presently has an average rating of “Buy” and an average target price of $42.14.
Heron Therapeutics (NASDAQ:HRTX) traded down 2.58% during mid-day trading on Friday, reaching $16.59. 245,642 shares of the company traded hands. The company’s 50-day moving average is $18.73 and its 200-day moving average is $18.90. Heron Therapeutics has a 12-month low of $15.13 and a 12-month high of $31.32.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/07/heron-therapeutics-inc-hrtx-to-post-q1-2017-earnings-of-0-77-per-share-leerink-swann-forecasts.html
Heron Therapeutics (NASDAQ:HRTX) last issued its quarterly earnings data on Monday, August 8th. The biotechnology company reported ($1.17) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.96) by $0.21.
In related news, insider Robert Rosen sold 100,000 shares of the company’s stock in a transaction that occurred on Wednesday, August 10th. The stock was sold at an average price of $23.30, for a total transaction of $2,330,000.00. Following the completion of the transaction, the insider now owns 102,640 shares in the company, valued at $2,391,512. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Corporate insiders own 20.31% of the company’s stock.
Several large investors have recently added to or reduced their stakes in the company. BlackRock Group LTD boosted its stake in Heron Therapeutics by 9.0% in the second quarter. BlackRock Group LTD now owns 10,816 shares of the biotechnology company’s stock worth $195,000 after buying an additional 897 shares in the last quarter. Parametric Portfolio Associates LLC bought a new stake in Heron Therapeutics during the second quarter worth approximately $213,000. BlackRock Advisors LLC boosted its stake in Heron Therapeutics by 13.3% in the second quarter. BlackRock Advisors LLC now owns 15,104 shares of the biotechnology company’s stock worth $273,000 after buying an additional 1,769 shares in the last quarter. State Board of Administration of Florida Retirement System boosted its stake in Heron Therapeutics by 8.3% in the second quarter. State Board of Administration of Florida Retirement System now owns 16,739 shares of the biotechnology company’s stock worth $302,000 after buying an additional 1,283 shares in the last quarter. Finally, American International Group Inc. boosted its stake in Heron Therapeutics by 8.1% in the second quarter. American International Group Inc. now owns 18,293 shares of the biotechnology company’s stock worth $330,000 after buying an additional 1,369 shares in the last quarter.
Heron Therapeutics Company Profile
Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.
Receive News & Ratings for Heron Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.